0001193125-25-267049
SEC filingBruker's Q3 2025 revenue declined 0.5% YoY, with GAAP operating loss driven by goodwill impairment and restructuring costs.
Bruker's consolidated revenue for the three months ended September 30, 2025, was $860.5 million, a decrease of 0.5% compared to $864.4 million in the same period of 2024. The decline was primarily driven by weaker demand in academic and government research markets for life science instruments, partially offset by growth in biopharma research and applied markets. GAAP gross profit fell 9.4% to $379.4 million, with gross margin contracting to 44.1% from 48.4% in the prior year. The margin compression was attributed to increased restructuring costs, impairment charges, higher U.S. tariffs, and foreign exchange headwinds from a declining U.S. dollar. GAAP operating income swung to a loss of $51.8 million from a profit of $68.1 million, largely due to a $96.5 million goodwill impairment charge recorded in the BSI Nano and BSI BioSpin segments. On a non-GAAP basis, operating income was $105.9 million, down from $129.1 million, with non-GAAP operating margin declining to 12.3% from 14.9%. Net loss attributable to Bruker Corporation was $59.6 million, compared to net income of $40.9 million in the prior year quarter.
Segment performance was mixed. The BSI CALID segment was the standout, with revenue increasing 11.9% to $312.7 million, driven by improvement in molecular diagnostics and the ELITechGroup acquisition. Its operating margin was 15.2%. The BSI BioSpin segment saw revenue decline 10.4% to $208.7 million, with operating margin falling to 4.1% from 21.0%, reflecting weaker demand and restructuring impacts. The BSI Nano segment revenue decreased 7.2% to $266.5 million, and reported an operating loss of $72.2 million, including the goodwill impairment charge. The BEST segment revenue grew 7.4% to $73.8 million, but operating margin declined to 6.2% from 11.2% due to softness in the clinical MRI market. Geographically, North American revenue decreased 4.8%, European revenue increased 7.8%, and Asia Pacific revenue decreased 3.8%.
Management announced a cost savings initiative in August 2025 aimed at reducing annual costs by approximately $100 million to $120 million by 2026, targeting supply chain, manufacturing, commercial operations, administrative functions, and R&D. The company expects these actions to positively impact operating income and margin. No specific revenue or earnings guidance was provided for future periods. The MD&A highlights ongoing macroeconomic uncertainties, including tariffs, foreign exchange volatility, and geopolitical tensions, which may continue to affect demand, particularly in academic and government research markets. The company also noted the impact of the OECD Pillar 2 global minimum tax, which increased the adjusted effective tax rate by 1.3% in Q3 2025 and 3.0% year-to-date.
As of September 30, 2025, Bruker held $293.1 million in cash and equivalents, slightly up from $183.4 million at year-end 2024. Total debt stood at $2,008.5 million, a net decrease of $85.8 million due to repayments of the 2019 Term Loan and revolver, partially offset by new preferred stock issuance of $669.5 million. Shareholders' equity increased to $2,449.5 million from $1,797.1 million, driven by the preferred stock and foreign currency translation gains. Inventory increased to $1,196.6 million, up 12% from $1,067.8 million, largely due to acquisitions and in-transit systems. Remaining performance obligations (RPO) were $2,079.2 million, indicating a healthy order backlog.
The notes disclose a legal accrual of $27.6 million as of September 30, 2025, relating to various patent litigations, including a $68 million settlement with 10x Genomics (paid in installments). No inventory or capacity purchase commitments were reported. The company has contingent consideration liabilities of $14.5 million and hybrid instrument liabilities of $39.8 million related to acquisitions.
During the nine months ended September 30, 2025, Bruker repurchased 200,731 shares for $10.0 million, with no remaining buyback authorization disclosed. Dividends to common shareholders totaled $22.9 million. Capital expenditures were $68.2 million, or 2.77% of revenue. Debt activity included $768.4 million in proceeds (mostly revolver draws) and $1,115.1 million in repayments, net reducing debt. The company also issued Series A Mandatory Convertible Preferred Stock, raising $669.5 million net.
Segment performance in Q3 2025 varied widely. BSI CALID posted the strongest growth (+11.9%) and highest operating margin (24.3%), driven by acquisitions and mass spectrometry demand. BSI NANO declined 7.2% with an 8.8% margin, impacted by a $96.5 million goodwill impairment in the spatial biology and automation reporting units. Revenue by geography showed the U.S. down 5.4%, China flat, and Europe excluding Germany up 11.9%.
Operating cash flow (CFO) deteriorated sharply to -$95.7M from $61.3M in the prior-year period, as a net loss of $37.5M (vs $99.9M income) and a $269M net working capital outflow (primarily income taxes payable and accounts payable) weighed on cash generation. Depreciation and amortization of $162.2M provided some offset, but non-cash impairments of $147.5M further reduced net income without cash impact. The capex intensity remained moderate at $68.2M (71% of prior-year CFO), though the current CFO deficit implies reliance on financing. Capital returns to shareholders totaled $25.3M (dividends $15.3M plus buybacks $10.0M), which were unfunded by operations. The company financed operations and investments via $669.5M in preferred stock issuance, $765.5M in revolving credit draws, and $2.9M in long-term debt, while repaying $793.8M in revolver and $321.3M in long-term debt. Overall, cash flow quality is weak due to negative CFO and reliance on external financing, with working capital swings and one-time tax payments ($186.2M) being notable anomalies.